MAP2K7 and Skin rash: Comparing the results obtained on the incidence profiles of the single most frequent side effects following the prescription of BRAF and MEK inhibitors, it is observed that the combination therapy with Vemurafenib and Cobimetinib is associated with a higher rate of diarrhea, arthralgia, and skin rash for any considered grade.